Clinical Analysis: Continuous Bleeding Despite/Due to Irregular OCP Use

Understanding What Happened - Step by Step

Why the Bleeding Won't Stop

1. Original AUB - Likely anovulatory. Unopposed estrogen led to a thickened, fragile endometrium with no progestin support. This is why she bled continuously for 1.5 months.
2. OCP for 21 days - The combined pill provided both estrogen AND progestin, building a well-organized endometrium. Stopping after 21 days caused a clean withdrawal bleed (correct).
3. The critical error - She restarted OCP only 3-4 days after stopping (i.e., mid-withdrawal bleed). At this point, the endometrium was partially shed and dyssynchronous. Adding back estrogen + progestin at this stage does NOT build an organized endometrium - it creates patchy, atrophic endometrium with fragile, poorly supported capillaries.
4. Breakthrough bleeding after 14-15 days - This represents the atrophic endometrium losing its blood supply support as it becomes too thin. The progestin in the OCP is causing endometrial atrophy but the capillaries are not supported, causing continuous low-level bleeding.

What to Do Now (Management)

1. If hemodynamically stable (no heavy flooding):

• Stop the OCP NOW
• Allow the withdrawal bleed to complete (2-4 days of bleeding expected - warn the patient about this)
• Restart OCP properly on Day 1 or Day 5 of the withdrawal bleed
• Take 21 days continuously, then stop for 7 days (classic 21/7 regimen)

• Give ONE OCP tablet every 6-8 hours for 5-7 days (monophasic pill preferred)
• Bleeding should stop within 24-48 hours
• Then taper to 1 tablet twice daily x 7 days, then 1 tablet daily
• Complete a full 21-day pack from that point
• Warn: Heavy withdrawal bleed will occur when pills are stopped
• Goldman-Cecil Medicine, p. 2556: "Even profuse bleeding in hemodynamically stable anovulatory women can almost always be successfully treated by the off-label administration of one combination oral contraceptive pill every 6 hours for 5 to 7 days. Bleeding should cease within 24 hours, but patients should be warned to expect heavy bleeding 2 to 4 days after therapy is stopped."

2. If bleeding is heavy (soaking >1 pad/hour):

• Consider IV conjugated estrogens 25 mg every 4 hours (up to 3 doses)
• Add norethisterone/medroxyprogesterone acetate simultaneously
• Tranexamic acid 500-1000 mg TDS can be added as an anti-fibrinolytic to slow blood loss
• NSAIDs (mefenamic acid) reduce blood loss by ~30% and help if cramping
• If severely anemic: blood transfusion may be needed

3. Long-term after bleeding is controlled:

• Properly cycled OCP for at least 3-6 cycles to allow endometrial remodeling
• Alternatively, norethisterone 5 mg twice daily for 21 days from Day 5, for 3 cycles
• Counsel patient strongly: Do not restart hormones mid-cycle or self-medicate - irregular use is worse than no use, because it creates an unstable endometrium
• Reassess for underlying cause (PCOS, thyroid disease, coagulation disorder) once patient trusts the clinical relationship enough to accept investigations

Investigations to Push For (Even If Declined)

• Pregnancy test (MUST, even if patient denies sexual activity)
• CBC - assess degree of anemia
• Thyroid function (hypothyroidism is a reversible cause of AUB)
• Pelvic USG - rule out polyp, fibroid, PCOS, endometrial thickness
• Coagulation screen if bleeding since menarche or family history
• Prolactin level

Key Teaching Point

• Hormonal fluctuations
• Disorganized endometrial development
• Atrophic endometrium with fragile, unsupported capillaries
• Breakthrough bleeding that does not self-terminate

The RACGP guidance on irregular bleeding with contraception notes that BTB is common in the first 3-4 months of COCP use but irregular/missed pill use is a major contributing factor that must be corrected before attributing bleeding to the pill itself.

Why the 21/7 OCP Regimen?

1. The Original Reason: Psychosocial Acceptability (Historical)

2. What Happens Pharmacologically in Each Phase

During the 21 days (active pills):

• Suppressing FSH and LH from the pituitary → ovulation is inhibited
• Progestin thins and atrophies the endometrium → reduces implantation potential
• Thickens cervical mucus → blocks sperm
• Alters tubal motility
• Katzung Pharmacology: "The combinations of estrogens and progestins exert their contraceptive effect largely through selective inhibition of pituitary function that results in inhibition of ovulation... also produce a change in the cervical mucus, in the uterine endometrium, and in motility and secretion in the uterine tubes."

During the 7-day break:

• Both estrogen AND progesterone are suddenly withdrawn
• The thin, atrophied endometrium loses hormonal support
• Withdrawal bleed occurs - it is lighter and shorter than a natural period because the endometrium is much thinner than in a spontaneous cycle
• Meanwhile, the pituitary begins to "wake up" - FSH starts rising by Day 5-7 of the break
• This is the critical pharmacological constraint: the break cannot be longer than 7 days, or the pituitary will recover enough to initiate folliculogenesis and potentially cause a breakthrough ovulation

3. Why Exactly 7 Days? - The Pharmacological Limit

4. Why 21 Days Active? - Enough Time to Suppress the Axis

• Maintain consistent suppression of the hypothalamo-pituitary-ovarian (HPO) axis
• Keep the endometrium in a stable, atrophic state
• Allow adequate cervical mucus thickening
• Provide reliable contraception with a Pearl Index <1% with perfect use

5. Is the 21/7 Regimen Medically Necessary?

• It is when escape ovulation is most likely
• It is when pill-related symptoms (headaches, dysmenorrhea, hormone withdrawal effects) peak
• It is when OCP users are most likely to miss pills on restart

6. Relevance to Your Patient

• The endometrium hadn't fully shed
• The new hormones were applied to an already disrupted, partially shed, disorganized endometrium
• This created an atrophic, dyssynchronous endometrium with fragile capillaries
• Result: uncontrolled breakthrough bleeding

21/7 OCP Regimen: Indications (Therapeutic & Contraceptive)

A. Gynecological Conditions

B. Dermatological / Endocrine Conditions

• Katzung Pharmacology: "Agents containing large amounts of estrogen usually cause marked improvement in acne... Hirsutism may be aggravated by 19-nortestosterone derivatives and combinations containing nonandrogenic progestins are preferred."

C. Protective / Cancer-Prevention Indications

• Katzung: "These compounds reduce the risk of endometrial and ovarian cancer."

D. When 21/7 is Preferred OVER Continuous Use

1. Patient wants a regular monthly bleed - for psychological reassurance of "not being pregnant"
2. Initial OCP users - easier to understand and comply with; predictable bleeding helps with counseling
3. AUB management - the monthly withdrawal bleed provides evidence that the endometrium is being properly controlled
4. Conditions where cyclic shedding is therapeutically useful - e.g., mild endometriosis where cyclic shedding of decidualized implants is acceptable
5. When monitoring cycle regularity is clinically important - in adolescents, in PCOS follow-up

E. When Continuous Use is PREFERRED Over 21/7

• Severe endometriosis - complete suppression without any monthly "flare" during the pill-free interval
• Catamenial epilepsy / migraine - seizures or migraines triggered by the hormone withdrawal during the 7-day break
• Severe PMS/PMDD - the pill-free interval still causes symptom relapse
• Sickle cell disease - menstruation triggers crises; amenorrhea is beneficial
• Military/sports athletes - convenience of no monthly bleeding

Quick Summary Table